Ignite Creation Date:
2025-12-17 @ 2:48 PM
Ignite Modification Date:
2025-12-23 @ 4:54 PM
Study NCT ID:
NCT05213195
Status:
RECRUITING
Last Update Posted:
2024-02-12
First Post:
2021-12-25
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
Sponsor:
Zhejiang University
Organization:
Study Overview
Official Title:
NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
Detailed Description:
NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer Will be intra-peritoneal infusion in Stage 1 and combined with intra-venous infusion in Stage 2. While in Stage 3, the investigators will expand to other cancer type at certain situation.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: